Does the media prefer PCRX or OGN?

In the previous week, Organon & Co. had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Organon & Co. and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Organon & Co.'s score of 0.82 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PCRX or GPCR?

In the previous week, Structure Therapeutics had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for Structure Therapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Structure Therapeutics' score of 1.40 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCRX or MBX?

In the previous week, MBX Biosciences had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for MBX Biosciences and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat MBX Biosciences' score of 1.01 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MBX Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TARS or PCRX?

In the previous week, Tarsus Pharmaceuticals had 13 more articles in the media than Pacira BioSciences. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Tarsus Pharmaceuticals' score of 1.63 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ARQT or PCRX?

In the previous week, Arcutis Biotherapeutics had 12 more articles in the media than Pacira BioSciences. MarketBeat recorded 14 mentions for Arcutis Biotherapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Arcutis Biotherapeutics' score of 1.15 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Pacira BioSciences (PCRX) Competitors

$25.76 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$25.77 +0.01 (+0.04%)

As of 03:59 AM Eastern

Compare

PCRX vs. OGN, GPCR, MBX, TARS, and ARQT

Should you buy Pacira BioSciences stock or one of its competitors? Pacira BioSciences's main competitors and comparable companies include Organon & Co. (OGN), Structure Therapeutics (GPCR), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Organon & Co.?

Pacira BioSciences (NASDAQ:PCRX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Pacira BioSciences presently has a consensus target price of $30.20, suggesting a potential upside of 17.24%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.21%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Organon & Co. has a net margin of 3.41% compared to Pacira BioSciences' net margin of 1.96%. Organon & Co.'s return on equity of 88.97% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Organon & Co.	3.41%	88.97%	6.03%

In the previous week, Organon & Co. had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 6 mentions for Organon & Co. and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Organon & Co.'s score of 0.82 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Pacira BioSciences. Organon & Co. is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.41	$7.03M	$0.35	73.60
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.88

Summary

Pacira BioSciences and Organon & Co. tied by winning 8 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Structure Therapeutics?

Pacira BioSciences (NASDAQ:PCRX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Pacira BioSciences currently has a consensus price target of $30.20, suggesting a potential upside of 17.24%. Structure Therapeutics has a consensus price target of $110.91, suggesting a potential upside of 134.13%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, suggesting that its share price is 243% less volatile than the broader market.

Pacira BioSciences has a net margin of 1.96% compared to Structure Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Structure Therapeutics	N/A	-25.56%	-24.31%

In the previous week, Structure Therapeutics had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for Structure Therapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Structure Therapeutics' score of 1.40 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Structure Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.41	$7.03M	$0.35	73.60
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Summary

Pacira BioSciences beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to MBX Biosciences?

Pacira BioSciences (NASDAQ:PCRX) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

In the previous week, MBX Biosciences had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for MBX Biosciences and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat MBX Biosciences' score of 1.01 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MBX Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 1.96% compared to MBX Biosciences' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
MBX Biosciences	N/A	-26.02%	-24.94%

Pacira BioSciences presently has a consensus target price of $30.20, indicating a potential upside of 17.24%. MBX Biosciences has a consensus target price of $77.00, indicating a potential upside of 22.22%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pacira BioSciences has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.41	$7.03M	$0.35	73.60
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

Pacira BioSciences beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 13 more articles in the media than Pacira BioSciences. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Tarsus Pharmaceuticals' score of 1.63 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pacira BioSciences has a net margin of 1.96% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Pacira BioSciences' return on equity of 9.68% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Pacira BioSciences	1.96%	9.68%	5.30%

Pacira BioSciences has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.98	-$66.42M	-$1.09	N/A
Pacira BioSciences	$726.41M	1.41	$7.03M	$0.35	73.60

Tarsus Pharmaceuticals currently has a consensus target price of $90.50, suggesting a potential upside of 26.11%. Pacira BioSciences has a consensus target price of $30.20, suggesting a potential upside of 17.24%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Pacira BioSciences beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Pacira BioSciences (NASDAQ:PCRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Pacira BioSciences has higher revenue and earnings than Arcutis Biotherapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Pacira BioSciences	$726.41M	1.41	$7.03M	$0.35	73.60

99.7% of Pacira BioSciences shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arcutis Biotherapeutics currently has a consensus target price of $35.57, suggesting a potential upside of 49.59%. Pacira BioSciences has a consensus target price of $30.20, suggesting a potential upside of 17.24%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Arcutis Biotherapeutics had 12 more articles in the media than Pacira BioSciences. MarketBeat recorded 14 mentions for Arcutis Biotherapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Arcutis Biotherapeutics' score of 1.15 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arcutis Biotherapeutics has a net margin of 6.15% compared to Pacira BioSciences' net margin of 1.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Pacira BioSciences	1.96%	9.68%	5.30%

Arcutis Biotherapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Pacira BioSciences on 11 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	73.60	787.65	273.17	25.45
Price / Sales	1.41	759.94	638.21	103.75
Price / Cash	6.68	15.32	28.74	36.03
Price / Book	1.60	10.49	11.08	6.36
Net Income	$7.03M	$2.83B	$3.48B	$349.79M
7 Day Performance	3.62%	0.58%	0.38%	-0.40%
1 Month Performance	-2.46%	5.69%	7.89%	4.24%
1 Year Performance	-3.41%	6.19%	24.71%	15.13%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCRX Pacira BioSciences	3.7708 of 5 stars	$25.76 flat	$30.20 +17.2%	-3.4%	$1.03B	$726.41M	73.60	720	Positive News
OGN Organon & Co.	1.8431 of 5 stars	$13.75 +0.0%	$11.40 -17.1%	+46.6%	$3.61B	$6.22B	17.86	10,000
GPCR Structure Therapeutics	2.1971 of 5 stars	$49.01 -0.2%	$110.91 +126.3%	+145.4%	$3.42B	N/A	N/A	136
MBX MBX Biosciences	2.4993 of 5 stars	$66.39 +0.1%	$77.00 +16.0%	+317.5%	$3.19B	N/A	N/A	N/A	Positive News Gap Down
TARS Tarsus Pharmaceuticals	3.5796 of 5 stars	$72.81 +0.2%	$90.50 +24.3%	+22.5%	$3.19B	$451.36M	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. OGN, GPCR, MBX, TARS, and ARQT

How does Pacira BioSciences compare to Organon & Co.?

Summary

How does Pacira BioSciences compare to Structure Therapeutics?

Summary

How does Pacira BioSciences compare to MBX Biosciences?

Summary

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. OGN, GPCR, MBX, TARS, and ARQT

How does Pacira BioSciences compare to Organon & Co.?

Do analysts recommend PCRX or OGN?

Do insiders & institutionals hold more shares of PCRX or OGN?

Is PCRX or OGN more profitable?

Does the media prefer PCRX or OGN?

Which has more volatility and risk, PCRX or OGN?

Which has stronger earnings and valuation, PCRX or OGN?

Summary

How does Pacira BioSciences compare to Structure Therapeutics?

Do analysts prefer PCRX or GPCR?

Do insiders and institutionals have more ownership in PCRX or GPCR?

Which has more volatility and risk, PCRX or GPCR?

Is PCRX or GPCR more profitable?

Does the media prefer PCRX or GPCR?

Which has better valuation & earnings, PCRX or GPCR?

Summary

How does Pacira BioSciences compare to MBX Biosciences?

Which has more volatility and risk, PCRX or MBX?

Does the media favor PCRX or MBX?

Is PCRX or MBX more profitable?

Do analysts recommend PCRX or MBX?

Do insiders & institutionals believe in PCRX or MBX?

Which has preferable valuation and earnings, PCRX or MBX?

Summary

How does Pacira BioSciences compare to Tarsus Pharmaceuticals?

Do insiders and institutionals hold more shares of TARS or PCRX?

Which has more volatility and risk, TARS or PCRX?

Does the media refer more to TARS or PCRX?

Is TARS or PCRX more profitable?

Which has higher valuation & earnings, TARS or PCRX?

Do analysts rate TARS or PCRX?

Summary

How does Pacira BioSciences compare to Arcutis Biotherapeutics?

Which has stronger valuation and earnings, ARQT or PCRX?

Do institutionals and insiders hold more shares of ARQT or PCRX?

Do analysts rate ARQT or PCRX?

Does the media prefer ARQT or PCRX?

Is ARQT or PCRX more profitable?

Which has more volatility & risk, ARQT or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools